Metabolic dysfunction–associated fatty liver disease (MAFLD) affects nearly one in four adults globally. In Asia Pacific, the trajectory is particularly concerning, yet most health systems remain oriented toward late-stage response rather than early detection.
This White Paper, developed in collaboration with a multidisciplinary regional Advisory Panel, provides the first comprehensive, comparative assessment of policy and system readiness across nine APAC territories: Australia, Hong Kong, India, Japan, South Korea, Malaysia, Thailand, Taiwan, and Vietnam.
Using a structured scorecard framework, the paper assesses where each territory stands across five domains - policy and governance, prevention and screening, diagnostic capacity, treatment access, and awareness - and identifies the structural gaps that continue to drive late diagnosis and rising system costs.
